Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2007: 97/2 (Feb) pp. 169-328
Pages: 254-262

Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells

Africa Fernandez-L. 1, Eva M. Garrido-Martin 1, Francisco Sanz-Rodriguez 1,3, Jose-Ramon Ramirez 4, Carmelo Morales-Angulo 2, Roberto Zarrabeitia 2, Alfonso Perez-Molino 2, Carmelo Bernabéu 1, Luisa-María Botella1
1 Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu, Madrid, Spain; 2 Unidad de HHT, Hospital de Sierrallana, Torrelavega, Santander, Spain; 3 Facultad de Biología, Universidad Autónoma de Madrid, Madrid, Spain; 4 Anatomia Patológica, Hospital C


fibrinolysis, endothelial cells, HHT, endoglin, ALK-1, tranexamic acid


Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic telangiectasia (HHT). Its treatment is difficult. Our objective was to assess the use of tranexamic acid (TA), an antifibrinolytic drug, for the treatment of epistaxis in HHT patients and to investigate in vitro the effects of TA over endoglin and ALK-1 expression and activity in endothelial cells.A prospective study was carried out on patients with epistaxis treated with oral TA in the HHT Unit of Sierrallana Hospital (Cantabria, Spain). Primary cultures of endothelial cells were treated with TA to measure the levels of endoglin and ALK-1 at the cell surface by flow cytometry. RNA levels were also measured by real-time PCR, and the transcriptional effects ofTA on reporters for endoglin, ALK-1 and the endoglin/ALK-1 TGF beta pathway were assessed.The results showed that the fourteen HHT patients treated orally withTA improved, and the frequency and severity of their epistaxis were decreased. No complications derived from the treatment were observed. Cultured endothelial cells incubated with TA exhibited increased levels of endoglin and ALK-1 at the protein and mRNA levels, enhanced TGF-β signaling, and improved endothelial cell functions like tubulogenesis and migration. In summary, oral administration of TA proved beneficial for epistaxis treatment in selected patients with HHT. In addition to its already reported antifibrinolytic effects, TA stimulates the expression ofALK-1 and endoglin,as well as the activity of the ALK-1/endoglin pathway.

You may also be interested in...

Anneke Hecke 1,2, Hilary Brooks1 , Matthieu Meryet-Figuière 2 , Stephanie Minne2 , Stavros Konstantinides2 , Gerd Hasenfuss2 , Bernard Lebleu1 *, Katrin Schäfer2 *

Thromb Haemost 2006 95 5: 857-864

A randomised, double blind trial

See also Herwald

Online Supplementary Material

C. Schoergenhofer, P. Matzneller (1), M. Mußbacher (2), J. A. Schmid (2), P. Jilma-Stohlawetz (3), M. Zeitlinger (1), B. Jilma

Thromb Haemost 2017 117 9: 1714-1721


Online Supplementary Material

E. Rossi (1, 2), D. Smadja (3), C. Goyard (1, 2, 4), A. Cras (1, 2, 5), B. Dizier (1, 2), N. Bacha (1, 2), A. lokajczyk (1, 2), C. L. Guerin (6), N. Gendron (7), B. Planquette (1, 2, 4), V. Mignon (1, 8), C. Bernabéu (9), O. Sanchez (1, 2, 4), D. M. Smadja (7)

Thromb Haemost 2017 117: -